DGAP-News: Formycon AG / Key word(s): Contract Formycon AG: Reappointment of board member Dr. Nicolas Combé 04.05.2015 / 10:11 --------------------------------------------------------------------- Munich - The Supervisory Board of Formycon AG has unanimously voted to extend the executive board appointment of Dr. Nicolas Combé, the co-founder of the company who has served with distinction as its chief financial officer since May 5, 2010. With effect from April 27, 2015, his executive appointment has now been extended for three further years, until June 16, 2018. Without this extension, his current term of office would otherwise have expired as of May 5, 2015. "This strong vote of confidence will ensure stability and continuity as the company moves forward in its current growth phase," noted Dr. Olaf Stiller, Chairman of the Supervisory Board. "The Supervisory Board has no doubt that Dr. Combé will continue his excellent work over the next three years." "I am grateful for this renewed expression of the Supervisory Board's confidence, and I look forward to meeting the challenges which lie ahead," said Dr. Combé. "I would also like to take this opportunity to thank the staff of Formycon and especially our CEO, my colleague on the executive board. I am highly optimistic that, working together, we will continue to be able to attain the ambitious objectives which we have set for our company." About Formycon: Formycon AG is a leading independent developer of biosimilars for global marketing and has become a recognized innovator in the field. The team of the company which has today become Formycon AG has extensive experience in the development of complex molecules. The company has already successfully licensed two protein-based product portfolios out to major pharmaceutical companies - in 2008 and 2011. Its specialist expertise allows the company to develop high-quality biosimilars that meet the strict requirements of the regulatory authorities in highly regulated countries and regions such as Europe and the USA. Formycon currently has three biosimilar candidates under development, the first of which has already been licensed out to Santo Holding GmbH, with further product development projects in the pipeline. Its aim is to be the first company in the world to present clinical data for each respective product candidate and on this basis to license these products out to major pharmaceutical and generics companies for further development. Alternatively, Formycon offers further development of its biosimilars all the way through to marketing authorization, as well as commercial production on behalf of its licensees. Contact: Formycon AG Fraunhoferstr. 15 82152 Martinsried/Planegg Germany phone +49 (0) 89 - 86 46 67 100 fax + 49 (0) 89 - 86 46 67 110 [email protected] // www.formycon.com Disclaimer: This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions which may be subject to variety of risks and uncertainties. The results actually achieved by Formycon AG may substantially differ from these forward-looking statements. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. --------------------------------------------------------------------- 04.05.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Formycon AG Fraunhoferstraße 145 82152 Planegg-Martinsried Germany Phone: 089 864667 100 Fax: 089 864667 110 Internet: www.formycon.com ISIN: DE000A1EWVY8 WKN: A1EWVY Listed: Regulated Unofficial Market in Berlin; Open Market (Entry Standard) in Frankfurt End of News DGAP News-Service --------------------------------------------------------------------- 352243 04.05.2015